Iatrogenic Septic Arthritis Following Radiologically Guided Joint Injection
Poster Dec 13, 2017
Dr Osian P James, Mrs Lisa Williams
Septic arthritis (SA) causes undoubted morbidity and ultimately mortality. Consequently, this carries grave significance to patients and profound medico-legal implications to health professionals when cases are iatrogenic. Following local cases of SA from radiologically-guided joint injections, we aimed to compare performance with the available standards and target improved services.
Three cases were identified from the departmental logbook. For complications stemming from SA, each patient required ITU admission, multiple surgical interventions and prolonged hospital admissions. Long-term sequelae included renal failure, cardiac arrhythmias, thromboembolic disease, distant infections and chronic pain.
Limited literature exists concerning the risk of SA following joint injection. Earlier papers (1969-1991) quote between 1:20,000-500,0001-3 and the Australian health service 1:20,000-75,0004. However, the most robust source - an Icelandic study (2008) determines a risk of 1:2,700; with 17.9% of SA cases originating from arthrocentesis5.
Over the past 6 years, 5,363 joint injections were performed in the Radiology Department of our 410-bed District General Hospital under both ultrasound and fluoroscopic guidance. Using a 6-year cut-off, this generates a 1:1788 risk of SA – considerably higher than the literature.
Questions were raised at multi-disciplinary meetings over the suitability of the facilities, adequate staff training and implications on future joint-replacement surgery. Positive findings included early involvement of Microbiology and that no cases originated from GPs performing ‘blind’ injections. Debate also exists in the literature concerning the optimal choice of sterilising agent5. Clearly, standards must be improved locally, and with the above learning points implemented we propose to re-audit.
Young Adult Women’s Relationship Status and HPV Risk Perceptions: A Barrier to HPV Vaccination?Poster
Human papillomavirus (HPV) vaccine rates continue to be low in the United States. Young women ages 18-26 years are eligible for catch-up vaccination but previous research shows that relationships status and percieved risk may be barriers to HPV vaccination. The purpose of this quantitative study was to assess the association between relationship status and perceived risk for HPV among young adult women.READ MORE
Treatment Options for Chronic Parvovirus Viremia in Pediatric Heart Transplant Patients in a Tertiary Care CenterPoster
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE
The Role of K13 in Artemisinin ResistancePoster
Plasmodium falciparum is evolving resistance to Artemisinin Combination Therapy. The gene with the strongest association with resistance is K13. K13 is an ortholog of the well characterized transcriptional regulator Keap1. In this work we transcriptionally characterized a mutant with a transposon inserted in the K13 promoter region which results in dysregulation of K13 at 2 points of the intraerythrocytic cycle of the life-cycle to identify the processes regulated by K13.READ MORE